IN8bio, Inc. (INAB) Analyst Estimates Annual - Discounting Cash Flows
INAB
IN8bio, Inc.
INAB (NASDAQ)
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
Number of Analysts 2 3 4 4 3 0
Estimated Revenue
Low 29.98 10.88 1.11 47.67 9.2 0
Average 29.98 10.88 1.11 47.67 9.2 0
High 29.98 10.88 1.11 47.67 9.2 0
Estimated EBITDA
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated EBIT
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated Net Income
Low -85.94 -118.9 -178.8 -92.1 -139.6 -953.4
Average -85.94 -20.95 -24.82 -92.1 -139.6 -904.9
High -85.94 -13.39 -23.56 -92.1 -139.6 -856.5
Estimated SGA Expenses
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated EPS
Low -1.6 -2.22 -3.34 -1.72 -2.61 -17.81
Average -1.6 -0.983 -1.69 -1.72 -2.61 -16.9
High -1.6 -0.25 -0.44 -1.72 -2.61 -15.99
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program